Basimglurant (DB11833): A Comprehensive Pharmacological and Clinical Development Report on a Repurposed mGluR5 Modulator

Executive Summary

Basimglurant is an investigational, orally bioavailable, small molecule drug that functions as a potent and selective negative allosteric modulator (NAM) of the metabotropic glutamate receptor 5 (mGluR5).[1] Its development history provides a compelling case study in modern pharmaceutical strategy, characterized by initial setbacks in broad indications followed by a strategic pivot to targeted rare diseases.

Originally developed by Roche and Chugai Pharmaceutical under the developmental codes RG-7090 and RO-4917523, Basimglurant was first evaluated for the treatment of Major Depressive Disorder (MDD) and Fragile X Syndrome (FXS).[4] This initial strategy was predicated on the prevailing hypotheses implicating glutamatergic system dysfunction in the pathophysiology of these conditions. Despite demonstrating a favorable pharmacokinetic profile suitable for once-daily dosing and being generally well-tolerated in early clinical studies, Basimglurant ultimately failed to meet its primary efficacy endpoints in pivotal Phase II clinical trials for both MDD and FXS.[5] The combination of insufficient efficacy and the emergence of concerning psychiatric adverse events in the FXS trial led Roche to discontinue its development programs for these indications.

Following its discontinuation by Roche, the asset was acquired by Noema Pharma, a clinical-stage biotech company. Noema has initiated a strategic repurposing of the compound, now designated NOE-101, for rare neurological disorders where the link between the drug's mechanism of action and the underlying disease pathophysiology is more direct and mechanistically supported. The current development pipeline focuses on two such conditions: pain associated with Trigeminal Neuralgia (TN) and seizures associated with Tuberous Sclerosis Complex (TSC).[8] Both disorders are characterized by neuronal hyperexcitability, a state that mGluR5 negative modulation is well-positioned to address.

Currently, Basimglurant is in late-stage clinical development under Noema Pharma's stewardship. A global Phase II/III trial (LibraTN) is underway for Trigeminal Neuralgia, an indication for which the U.S. Food and Drug Administration (FDA) has granted Fast Track designation, signifying the high unmet medical need.[9] A Phase IIb trial (Galene) for seizures in TSC has recently been completed.[11] The trajectory of Basimglurant exemplifies a shift from a high-risk "blockbuster" drug development model to a more targeted, precision-medicine approach, demonstrating that a compound with a well-characterized profile can find new potential when its mechanism is precisely matched to a well-defined disease pathology.

Compound Profile: Identification and Physicochemical Properties

A thorough understanding of Basimglurant's fundamental chemical identity and physical properties is essential for interpreting its pharmacological behavior, pharmacokinetic profile, and formulation development.

Nomenclature and Chemical Identifiers

Throughout its multi-stage development history, Basimglurant has been referred to by a variety of names and codes. Establishing a clear reference for this nomenclature is critical for navigating the scientific and clinical literature. The compound's International Nonproprietary Name (INN) is Basimglurant.[4] During its initial development by Roche and Chugai Pharmaceutical, it was known by the developmental codes RG-7090, RO-4917523, and RO4917523.[1] It has also been referred to as a "CTEP Derivative" in some research contexts, referencing its structural relationship to another mGluR5 modulator.[14] Under its current development by Noema Pharma, it is designated NOE-101.[8] For unambiguous identification, it is cataloged in major chemical and drug databases under specific identifiers, which are summarized in Table 1.

Table 1: Key Identifiers for Basimglurant

Identifier Type	Value	Source/Context
DrugBank Accession Number	DB11833	DrugBank Database 1
CAS Number	802906-73-6	Chemical Abstracts Service 1
UNII	3110E3AO8S	Unique Ingredient Identifier 1
PubChem CID	11438771	PubChem Database 4
ChEMBL ID	CHEMBL3301626	ChEMBL Database 4
IUPHAR/BPS ID	9309	IUPHAR/BPS Guide to PHARMACOLOGY 4
KEGG ID	D10864	Kyoto Encyclopedia of Genes and Genomes 4
InChI Key	UPZWINBEAHDTLA-UHFFFAOYSA-N	IUPAC International Chemical Identifier 1

Chemical Structure and Classification

Basimglurant is a small molecule drug with a precisely defined chemical structure.[1] Its formal IUPAC (International Union of Pure and Applied Chemistry) name is 2-chloro-4-{[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-yl]ethynyl}pyridine.[4]

Structurally, it belongs to the class of organic compounds known as phenylimidazoles. This classification denotes polycyclic aromatic compounds that feature a benzene ring linked to an imidazole ring through either a carbon-carbon (C-C) or carbon-nitrogen (C-N) bond.[1] The molecule also contains an alkyne functional group, which makes it a useful tool in laboratory settings as a click chemistry reagent. Specifically, it can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc), a highly efficient reaction used for bioconjugation and molecular labeling.[3]

Key structural representations used for computational chemistry and database searching include:

• SMILES (Simplified Molecular-Input Line-Entry System): CC1=NC(C#CC2=CC=NC(Cl)=C2)=C(C)N1C1=CC=C(F)C=C1 [1]
• InChI (IUPAC International Chemical Identifier): InChI=1S/C18H13ClFN3/c1-12-17(8-3-14-9-10-21-18(19)11-14)22-13(2)23(12)16-6-4-15(20)5-7-16/h4-7,9-11H,1-2H3 [1]

Physicochemical Characteristics and Drug-Likeness

The physicochemical properties of Basimglurant govern its absorption, distribution, metabolism, and excretion (ADME), and ultimately influence its efficacy and safety profile. The molecule has a chemical formula of C18​H13​ClFN3​ and an average molecular weight of 325.77 g/mol.[1]

A critical characteristic of Basimglurant is its lipophilicity and low aqueous solubility. Its water solubility is predicted to be very low at 0.00504 mg/mL.[1] Conversely, its partition coefficient (logP), a measure of lipophilicity, is high, with predicted values ranging from 4.04 to 4.32.[1] This combination of properties is typical for a drug designed to penetrate the central nervous system, as lipophilicity facilitates crossing the blood-brain barrier. Other notable properties include a strongest basic pKa of 5.46, indicating it is a weak base, and a polar surface area of 30.71 Ų, which is relatively small and also conducive to membrane permeability.[1]

Computationally, Basimglurant exhibits favorable "drug-like" characteristics. It adheres to several widely used medicinal chemistry filters designed to predict oral bioavailability and metabolic stability, including Lipinski's Rule of Five, the Ghose Filter, and Veber's Rule.[1] A summary of these properties is provided in Table 2.

Table 2: Summary of Physicochemical Properties

Property	Value	Source
Molecular Formula	C18​H13​ClFN3​	1
Average Molecular Weight	325.77 g/mol	1
Water Solubility	0.00504 mg/mL	1
logP (Lipophilicity)	4.04 - 4.32	1
pKa (Strongest Basic)	5.46	1
Hydrogen Bond Acceptors	2	1
Hydrogen Bond Donors	0	1
Polar Surface Area	30.71 Ų	1
Lipinski's Rule of Five	Yes	1
Ghose Filter	Yes	1
Veber's Rule	Yes	1

The physicochemical profile of Basimglurant has had a direct and profound impact on its clinical development strategy. The compound's high lipophilicity and rapid absorption characteristics, while beneficial for achieving CNS penetration, were found to contribute to high peak plasma concentrations (Cmax​) when administered in an immediate-release (IR) formulation.[21] In clinical studies, a direct correlation was established between this high

Cmax​ and the incidence of dizziness, the most frequently reported adverse event.[21] This on-target side effect presented a significant tolerability challenge. To address this, developers engineered a modified-release (MR) formulation. The MR tablet was specifically designed to alter the absorption profile, successfully reducing the

Cmax​ by approximately 50% and prolonging the time to reach it (Tmax​) to around 5 hours.[21] This formulation-based solution was a critical step to improve the drug's safety and tolerability, enabling the use of therapeutically relevant doses while minimizing the primary dose-limiting side effect.

Core Pharmacology and Mechanism of Action

Basimglurant's therapeutic rationale is rooted in its highly specific interaction with a key receptor in the glutamatergic system, the most widespread excitatory neurotransmitter system in the central nervous system.

Primary Target: The Metabotropic Glutamate Receptor 5 (mGluR5)

The sole pharmacological target of Basimglurant is the metabotropic glutamate receptor 5 (mGluR5).[1] mGluR5 is a member of the Group I mGluR family, which are G-protein coupled receptors (GPCRs) that bind the neurotransmitter glutamate.[23] Upon activation by glutamate, mGluR5 couples to Gq/G11 proteins, initiating a downstream signaling cascade that involves the activation of phospholipase C (PLC).[1] PLC then catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (

PIP2​) into two second messengers: inositol 1,4,5-trisphosphate (IP3​) and diacylglycerol (DAG). This leads to the mobilization of intracellular calcium (Ca2+) from the endoplasmic reticulum and the activation of Protein Kinase C (PKC), triggering a wide array of cellular responses.[1]

mGluR5 is abundantly expressed throughout the CNS, with particularly high concentrations in brain regions critical for higher-order functions, such as the cerebral cortex, hippocampus, and striatum.[24] Through its signaling pathways, mGluR5 plays a fundamental role in modulating synaptic plasticity—the ability of synapses to strengthen or weaken over time—which is the cellular basis of learning and memory.[1] It also regulates neuronal excitability and pain perception.[26] Given its central role in these processes, dysregulation of mGluR5 signaling has been implicated in the pathophysiology of numerous neurological and psychiatric disorders, including depression, anxiety, Fragile X syndrome, epilepsy, and chronic pain.[24]

Mechanism of Negative Allosteric Modulation (NAM)

Basimglurant acts as a negative allosteric modulator (NAM) of the mGluR5 receptor.[2] Unlike a competitive antagonist, which would bind to the same site as glutamate (the orthosteric site) and directly block its action, a NAM binds to a distinct, topographically separate site on the receptor protein.[29] This binding induces a conformational change in the receptor that reduces its affinity for glutamate or its ability to activate G-protein signaling upon glutamate binding. This allosteric mechanism provides a more subtle, "dimmer-switch" form of inhibition rather than a simple "on-off" blockade, which can offer a more favorable therapeutic window.

Basimglurant is both highly potent and selective for mGluR5. In vitro binding assays have demonstrated a high affinity, with a dissociation constant (Kd​) of 1.1 nM.[2] Functional assays confirm this potency; in HEK293 cells engineered to express human mGluR5, Basimglurant inhibits agonist-induced calcium mobilization and inositol phosphate accumulation with half-maximal inhibitory concentrations (

IC50​) of 7.0 nM and 5.9 nM, respectively.[3] This high degree of selectivity for mGluR5 over other mGluR subtypes and other CNS receptors is a key pharmacological feature, minimizing the potential for off-target side effects.[26]

Preclinical Pharmacodynamic Profile

The therapeutic potential of Basimglurant was first established through a comprehensive preclinical testing program in various animal models, which provided the rationale for its initial clinical development in psychiatric disorders and its subsequent repurposing for neurological conditions.

• Antidepressant and Anxiolytic Effects: In rodent models of depression and anxiety, Basimglurant exhibited robust and consistent efficacy. Its antidepressant-like properties were corroborated by functional magnetic resonance imaging (fMRI) studies in animals.[3] In some behavioral tests for anxiety, it demonstrated efficacy comparable to the benzodiazepine diazepam, but at significantly lower doses, suggesting a potent anxiolytic-like profile.[26] These findings formed the primary basis for advancing Basimglurant into clinical trials for Major Depressive Disorder.
• Antinociceptive Effects: Preclinical studies also revealed that Basimglurant possesses antinociceptive features, meaning it can reduce the perception of pain.[3] Animal models of neuropathic pain showed that the compound was effective at controlling pain, an effect thought to be mediated by reducing over-signaling in nociceptive circuits.[8] This preclinical signal is the foundational evidence supporting its current development by Noema Pharma for Trigeminal Neuralgia.
• Wake-Promoting Effects: Electroencephalography (EEG) recordings in rodents showed that Basimglurant administration produced wake-promoting effects.[26] This was considered a potentially valuable attribute for an antidepressant, as it suggested the possibility of addressing common MDD comorbidities such as daytime sleepiness, apathy, and lethargy.[26]

The mechanism of action of Basimglurant, while conferring therapeutic potential, also inherently carries specific risks. The drug's primary function is to dampen excitatory glutamatergic signaling, which is the basis for its utility in conditions of neuronal hyperexcitability like seizures and neuropathic pain. However, glutamatergic pathways, particularly the finely tuned interplay between mGluR5 and N-methyl-D-aspartate (NMDA) receptors, are also critical for normal cognitive and perceptual processes.[26] Disruption of this system can lead to significant psychiatric side effects. This was borne out in clinical trials, where the most severe, albeit rare, adverse events were directly linked to the drug's on-target pharmacology. In the Fragile X syndrome trial, a higher incidence of hallucinations and psychosis was observed [5], and in the MDD trial, two cases of mania were reported.[22] This suggests that by modulating a fundamental excitatory pathway, the drug carries an intrinsic risk of inducing psychiatric symptoms. This creates a therapeutic window challenge, where the dose required for efficacy may approach a dose that causes unacceptable side effects. This risk-profile likely contributed to the decision to halt development for broad psychiatric populations but is considered more acceptable in the context of treating severe, refractory neurological conditions like TN and TSC, where the unmet medical need is greater and the benefit-risk assessment is fundamentally different.

Human Pharmacokinetics: A Complete ADME Profile

The disposition of Basimglurant in the human body has been thoroughly characterized through a series of clinical pharmacology studies, most notably a sophisticated double-tracer study that allowed for the simultaneous determination of absolute bioavailability and a complete mass balance profile.[33] These studies reveal a compound with favorable drug-like properties, including good oral absorption and a long half-life supportive of once-daily dosing.

Absorption and Bioavailability

Basimglurant is well-absorbed after oral administration. The definitive human study involved administering a single 1 mg oral dose of radiolabeled (14C) Basimglurant concurrently with a 100 µg intravenous (IV) microdose of a stable isotope-labeled (13C6​) version of the drug.[33] By comparing the plasma exposure from the oral and IV doses, the mean absolute oral bioavailability (F) was determined to be approximately 67%, with a range of 45.7% to 77.7% across subjects.[30] This indicates that a substantial majority of the orally administered drug reaches the systemic circulation.

The rate of absorption for the immediate-release (IR) formulation is rapid. The median time to reach peak plasma concentration (Tmax​) after an oral dose was 0.71 hours (range 0.58-1.00 hours).[33] As previously noted, this rapid rise in plasma concentration was linked to the adverse event of dizziness. The development of a modified-release (MR) formulation was undertaken to blunt this peak, successfully prolonging the

Tmax​ to approximately 5 hours and reducing the Cmax​ by about half, thereby improving tolerability.[21]

Distribution

Once absorbed, Basimglurant distributes extensively throughout the body. Pharmacokinetic modeling from the IV microdose data revealed a large mean volume of distribution at steady state (Vss​) of 677 ± 229 L.[33] This value, which is many times the total body water volume, indicates that the drug does not remain confined to the bloodstream but partitions extensively into peripheral tissues, including its target organ, the brain. The drug was specifically designed for good brain penetration, a prerequisite for a CNS-acting compound.[3]

In the bloodstream, preclinical data indicates that Basimglurant is highly bound to plasma proteins, with a binding rate between 98% and 99%.[4] This is an important consideration, as only the small, unbound fraction of the drug is free to distribute into tissues and exert a pharmacological effect. The double-tracer study also showed minimal binding of the drug to red blood cells.[33]

Metabolism and Drug-Drug Interactions (DDIs)

Basimglurant is cleared from the body primarily through metabolic transformation in the liver, mediated by the cytochrome P450 (CYP) enzyme system.[21] Detailed

in vitro phenotyping studies have elucidated the specific enzymes involved. At the low plasma concentrations achieved with clinical doses, metabolism is dominated by CYP1A2, which is responsible for approximately 70% of the drug's clearance. CYP3A4 and CYP3A5 collectively contribute the remaining 30%.[35]

An unusual feature of Basimglurant's metabolism is its concentration dependency, which arises from the different kinetic profiles of the enzymes involved. Metabolism by CYP1A2 follows standard Michaelis-Menten kinetics. In contrast, CYP3A4 and CYP3A5 exhibit sigmoidal (cooperative) kinetics, meaning their metabolic efficiency increases disproportionately as the drug concentration rises. This interplay results in a shifting contribution of the enzymes to overall metabolism depending on the substrate concentration, with CYP3A4/5 playing a larger role at higher exposures.[35]

Given the reliance on CYP enzymes for clearance, dedicated clinical studies were conducted to assess the potential for drug-drug interactions (DDIs). These trials evaluated the pharmacokinetics of a single dose of Basimglurant when co-administered with steady-state doses of fluvoxamine (a strong CYP1A2 inhibitor), ketoconazole (a strong CYP3A4 inhibitor), and carbamazepine (a strong CYP3A4 inducer).[35] The results of these studies indicated a low potential for clinically significant DDIs, de-risking the compound for use in patient populations that are often on multiple medications.[35]

Five metabolites of Basimglurant have been identified in humans, with a glucuronide conjugate (M1-Glucuronide) being the most prominent. The other metabolites are present in only trace amounts.[33]

Excretion

The primary route of elimination for Basimglurant and its metabolites is via the kidneys. The human mass balance study, which tracked the excretion of the 14C-labeled oral dose, found that a mean of 73.4% of the total radioactivity was recovered in urine over the collection period. The remainder of the dose, a mean of 26.5%, was excreted in the feces, likely representing both unabsorbed drug and metabolites eliminated through the bile.[30]

Basimglurant has a very long elimination half-life, which supports a convenient once-daily dosing regimen. The mean terminal half-life (t1/2​) of the parent drug was calculated to be 77.2 ± 38.5 hours.[33] The terminal half-life of the total radioactivity was even longer, at 178 hours, indicating the presence of one or more metabolites that are cleared more slowly than the parent compound.[30] A summary of key human pharmacokinetic parameters is provided in Table 3.

Table 3: Summary of Human Pharmacokinetic Parameters

Parameter	Value	Source
Absolute Bioavailability (F)	~67% (Range: 45.7-77.7%)	33
Tmax​ (Oral, IR)	0.71 h (Median)	33
Terminal Half-Life (t1/2​)	77.2 ± 38.5 h (Parent Drug)	33
Terminal Half-Life (t1/2​)	178 h (Total Radioactivity)	33
Volume of Distribution (Vss​)	677 ± 229 L	33
Clearance (CL)	11.8 ± 7.4 mL/h	33
Primary Excretion Route	Urine (~73.4%)	33

The comprehensive and favorable pharmacokinetic profile established by Roche was a critical factor in the drug's viability for repurposing. A compound with poor absorption, rapid clearance, or significant DDI liabilities is often difficult to salvage regardless of its mechanism. Basimglurant, however, failed its initial clinical tests due to a lack of efficacy, not because of fundamental flaws in its drug-like properties. The existence of a robust ADME and DDI data package, demonstrating good bioavailability, a long half-life, and a low risk of interactions, made it an attractive asset for a company like Noema Pharma. This high-quality characterization work significantly de-risked the compound from a developmental standpoint, allowing the new sponsor to focus on demonstrating efficacy in more mechanistically appropriate indications.

Clinical Development History: The Roche Era

The initial clinical development of Basimglurant by Roche was ambitious, targeting two large and challenging psychiatric indications based on promising, yet ultimately non-translatable, preclinical data and scientific hypotheses. The outcomes of these Phase II trials were pivotal, leading to the discontinuation of the programs and setting the stage for the drug's later repurposing.

Indication 1: Major Depressive Disorder (MDD)

The rationale for investigating Basimglurant in MDD stemmed from the growing body of evidence supporting a "glutamatergic hypothesis of depression".[32] This hypothesis proposed that dysregulation in cortical glutamate pathways was a core pathophysiological feature of the disorder. As an mGluR5 NAM, Basimglurant offered a novel, non-monoaminergic mechanism of action to modulate this system. This was seen as a promising approach for patients who had an inadequate response to standard-of-care treatments like selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).[6] Strong preclinical data showing antidepressant-like effects in animal models further supported this strategy.[26]

Following successful Phase I studies that established the drug's safety, tolerability, and pharmacokinetic profile in both healthy volunteers and MDD patients (NCT02433093) [38], Roche initiated a large Phase IIb study.

Phase IIb Trial Analysis (MARIGOLD Study - NCT01437657)

The MARIGOLD study was a global, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of Basimglurant as an adjunctive therapy.[6] The trial enrolled 333 adult patients with MDD who were experiencing an inadequate response to their ongoing antidepressant medication.[6] Participants were randomized to receive one of two doses of Basimglurant modified-release (MR) (0.5 mg or 1.5 mg) or a placebo, once daily for six weeks, in addition to their existing treatment.[6]

The study's primary endpoint was the mean change from baseline to week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS), a standard clinician-rated measure of depressive symptom severity. The trial failed to meet this primary endpoint.[6] For the 1.5 mg dose, the improvement on the clinician-rated MADRS was not statistically significant compared to placebo (mean change of -16.1 vs -14.6; p=0.42).[6]

However, the trial produced a complex and intriguing set of results on its secondary endpoints. A notable divergence was observed between clinician-rated and patient-rated outcomes. While the clinician-rated primary endpoint was negative, the 1.5 mg dose of Basimglurant demonstrated statistically significant improvements over placebo on several patient-rated measures. These included the patient-rated MADRS (p=0.04), the Quick Inventory of Depressive Symptomatology-Self-Report (QUIDS-SR) (p=0.009), and the patient-rated MADRS remission rate (36.0% vs 22.0%; nominal p=0.03).[6] The 0.5 mg dose showed no benefit over placebo on any measure.[6]

Despite the encouraging signals from patient-reported outcomes, the definitive failure on the pre-specified primary endpoint was a critical setback. This negative result, likely exacerbated by a high placebo response rate commonly seen in antidepressant trials, made it difficult to justify the substantial investment required for Phase III development in the highly competitive MDD market.[32]

Indication 2: Fragile X Syndrome (FXS)

The investigation of Basimglurant for FXS was driven by the influential "mGluR theory of Fragile X".[31] This theory posits that the absence of the Fragile X Mental Retardation Protein (FMRP) leads to exaggerated protein synthesis downstream of mGluR5 activation. This unchecked signaling is believed to cause many of the synaptic abnormalities and behavioral symptoms characteristic of FXS. Preclinical research in

Fmr1 knockout mice, the primary animal model for FXS, showed that pharmacological inhibition of mGluR5 with NAMs could correct a wide range of these deficits, providing a compelling, mechanism-based rationale for human trials.[5]

Phase II Trial Analysis (FragXis Study)

The FragXis study was a 12-week, randomized, double-blind, placebo-controlled, parallel-group trial that enrolled 183 adolescents and adults (ages 14-50) with a confirmed full mutation in the FMR1 gene.[5] Participants were randomized to receive once-daily Basimglurant at doses of 0.5 mg or 1.5 mg, or placebo.[31]

The primary efficacy endpoint was the change from baseline in behavioral symptoms as measured by the total score on the Anxiety Depression and Mood Scale (ADAMS). The trial was a clear failure, as Basimglurant did not demonstrate any improvement over placebo.[5] In fact, the results trended in the wrong direction: both the 0.5 mg and 1.5 mg Basimglurant groups showed less improvement on the ADAMS total score than the placebo group.[5]

Compounding the lack of efficacy, the study raised new safety concerns. A higher incidence of adverse events classified as psychiatric disorders was reported in the patients treated with Basimglurant. This included three severe cases of hallucinations or psychosis, which were particularly concerning in this vulnerable patient population.[5]

The combination of a definitive lack of efficacy on the primary endpoint and the emergence of serious psychiatric safety signals led Roche to terminate the FXS development program.[4] This outcome, coupled with the concurrent failure of another mGluR5 NAM, mavoglurant (developed by Novartis), in a similar FXS trial, dealt a significant blow to the mGluR theory as a therapeutic strategy for neurodevelopmental disorders.[43] These failures prompted a broad re-evaluation within the scientific community regarding the translatability of preclinical findings from rodent models to complex human neurodevelopmental conditions and highlighted the immense challenges in clinical trial design, including patient heterogeneity and the selection of appropriate outcome measures.[43]

Table 4: Comparative Summary of Roche Phase II Trials (MDD & FXS)

	MARIGOLD Study (MDD)	FragXis Study (FXS)
Trial Identifier	NCT01437657	NP27936
Indication	Major Depressive Disorder (Adjunctive)	Fragile X Syndrome
Patient Population	333 adults with inadequate response to SSRI/SNRI	183 adolescents & adults with FMR1 full mutation
Doses Tested	0.5 mg & 1.5 mg MR vs. Placebo	0.5 mg & 1.5 mg vs. Placebo
Primary Endpoint	Change in clinician-rated MADRS score	Change in ADAMS total score
Primary Outcome	FAILED. No significant difference vs. placebo.	FAILED. Performed worse than placebo.
Key Secondary / Safety	- Statistically significant improvement on patient-rated scales (MADRS, QUIDS-SR).6	- Two cases of mania in 1.5 mg arm.22
Development Decision	Discontinued	Discontinued

Consolidated Safety and Tolerability Profile

The safety and tolerability of Basimglurant have been evaluated across multiple Phase I and Phase II clinical trials involving over 500 healthy volunteers and patients with MDD and FXS.[6] The overall assessment from these studies is that the drug is "generally well-tolerated," but with a distinct profile of adverse events (AEs) that are directly related to its pharmacological mechanism and pharmacokinetic properties.[30]

Overview of Adverse Events

The most frequently observed AEs across the clinical programs were within the nervous system disorders class.[22] In the pivotal MDD trial, the most common AEs (occurring in at least 5% of patients in any treatment arm) were dizziness, somnolence, and headache.[22] While generally manageable, these on-target CNS effects define the drug's primary tolerability burden.

Analysis of Key Safety Signals

Two key safety signals have emerged from the clinical data: a common, dose-dependent, and manageable AE (dizziness), and a rare but more serious class of psychiatric AEs.

• Dizziness: This is the most common adverse event associated with Basimglurant treatment. In the Phase IIb MDD study, dizziness was reported by 23.4% of patients in the 1.5 mg arm, compared to just 4.5% in the 0.5 mg arm and 5.5% in the placebo arm, clearly demonstrating a dose-dependent relationship.[22] The dizziness was characterized as being mostly transient and of mild-to-moderate intensity, typically resolving within a few days without intervention.[6] A dedicated population pharmacokinetic/pharmacodynamic analysis confirmed a statistically significant correlation between the incidence of dizziness and the peak plasma concentration ( Cmax​) of the drug.[21] This finding validated the development of the modified-release (MR) formulation as a rational strategy to improve tolerability by lowering Cmax​.[21]
• Psychiatric Adverse Events: This represents the most significant safety concern for Basimglurant. While infrequent, the nature of these events warrants careful consideration.
• In the FragXis trial in adolescents and adults with FXS, a higher incidence of psychiatric disorders was reported in the Basimglurant arms compared to placebo. Most notably, this included three serious cases of hallucinations or psychosis.[5]
• In the MARIGOLD trial for MDD, mania was reported in two patients in the 1.5 mg arm, both of whom were subsequently withdrawn from the study. The events resolved spontaneously after discontinuation.[22]
• No clear association with suicidality was observed, with rates of suicidal ideation being low and comparable across all treatment groups.[22]

Overall Risk-Benefit Assessment

The safety profile of Basimglurant has been a critical determinant in its developmental trajectory. The profile effectively acts as a filter, shaping which clinical indications are viable for pursuit. For a broad indication like MDD, where numerous alternative treatments exist, the risk of inducing mania, even if rare, presents a substantial hurdle for regulatory approval and commercial acceptance. For FXS, a vulnerable population with pre-existing behavioral challenges, the observed risk of psychosis and hallucinations was a major factor in the decision to halt the program, particularly in the absence of any demonstrated efficacy.

However, this same risk profile can be viewed differently in the context of severe, refractory diseases with high unmet medical need. For conditions like Trigeminal Neuralgia, often described as one of the most excruciating pain syndromes, or for uncontrolled seizures in TSC, the potential benefit of a novel therapeutic may outweigh the known risks. The strategic decision by Noema Pharma to pursue these indications implicitly acknowledges the established safety profile of Basimglurant, operating on the premise that the benefit-risk equation is more favorable in these specific, high-need patient populations than it was for MDD or FXS.

The Noema Pharma Era: A Strategic Repurposing

Following the discontinuation of Basimglurant by Roche, the compound has been given a second life by Noema Pharma. Under the new developmental code NOE-101, the drug is being repurposed with a precision-medicine strategy, targeting rare neurological disorders where its mechanism of action is tightly linked to the core pathophysiology of the disease. This approach moves away from broad psychiatric hypotheses and toward targeted intervention in diseases of neuronal hyperexcitability.

New Indication I: Trigeminal Neuralgia (TN)

Trigeminal Neuralgia is a chronic and debilitating neuropathic pain condition characterized by severe, paroxysmal, electric shock-like pain in the face.[45] The underlying pathophysiology is believed to involve hyperexcitability of the trigeminal nerve, often due to demyelination or neurovascular compression, leading to aberrant and excessive neuronal firing.[48] This state of neuronal hyperexcitability is driven by glutamatergic signaling.[27] Therefore, using an mGluR5 NAM like Basimglurant to dampen this overactive signaling in nociceptive circuits represents a direct, mechanism-based therapeutic strategy.[8] This offers a novel approach distinct from the current standard of care, which primarily relies on anticonvulsants like carbamazepine that act on sodium channels.[10]

The LibraTN Phase II/III Trial (NCT05217628)

To evaluate Basimglurant in this indication, Noema Pharma has initiated the LibraTN study, a pivotal global Phase II/III clinical trial.[8]

• Design: The study employs a powerful and efficient randomized withdrawal design. It begins with an 8-week, open-label run-in phase where all eligible patients are treated with Basimglurant, with the dose titrated from 1.5 mg to 3.5 mg daily based on individual efficacy and tolerability. Patients who demonstrate a clinical response during this phase are then randomized in a double-blind fashion to either continue their effective dose of Basimglurant or switch to a placebo for a 12-week period. The trial also includes a 52-week open-label extension to gather long-term safety and efficacy data.[45] This design is particularly well-suited for chronic pain conditions, as it aims to confirm that the observed benefit is due to the drug and not a placebo effect.
• Population: The trial is enrolling adults aged 18-75 with a confirmed diagnosis of primary Trigeminal Neuralgia who are not achieving adequate pain control with their current therapies.[45]
• Endpoints: The primary objective is to evaluate the efficacy of Basimglurant in reducing the number and/or severity of TN pain paroxysms. Efficacy will be measured using patient-reported outcomes, including daily pain diaries and the Patient-reported Global Impression of Change (PGI-C) scale.[45]
• Status and Regulatory Recognition: The trial is ongoing, with top-line data anticipated in the first half of 2024.[53] In recognition of the significant unmet need in TN and the promising mechanism of Basimglurant, the U.S. FDA has granted the program Fast Track designation. This is intended to facilitate development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.[9]

New Indication II: Tuberous Sclerosis Complex (TSC)

Tuberous Sclerosis Complex is a rare genetic disorder caused by mutations in either the TSC1 or TSC2 gene, which leads to constitutive hyperactivation of the mammalian target of rapamycin (mTOR) signaling pathway.[54] This results in the growth of benign tumors in multiple organs and is associated with severe neurological manifestations, including cortical malformations, intellectual disability, autism spectrum disorder, and refractory epilepsy.[55] There is a strong mechanistic link between the overactive mTOR pathway and glutamatergic signaling. Preclinical research using a mouse model of TSC demonstrated that the behavioral and epileptic phenotypes could be corrected by inhibiting mGluR5 with a NAM. In these models, mGluR5 inhibition reduced hyperactivity, decreased seizure frequency, and normalized the elevated rates of synaptic protein synthesis, providing a robust scientific rationale for investigating Basimglurant in TSC patients.[57]

The Galene Phase IIb Trial (NCT05059327)

Based on this strong preclinical evidence, Noema Pharma initiated the Galene study, a Phase IIb trial to assess Basimglurant's efficacy in controlling seizures associated with TSC.[60]

• Design: The study is a multicenter, 30-week, randomized, double-blind, placebo-controlled, cross-over trial. In this design, each participant receives both Basimglurant and placebo (in a random order) for distinct periods, serving as their own control. This is a highly efficient design for reducing variability in rare disease trials. The double-blind phase is followed by a 52-week open-label extension, allowing all participants the opportunity to receive the active drug long-term.[11]
• Population: The trial enrolled 61 children, adolescents, and young adults, aged 5 to 30 years, with a documented history of TSC and refractory seizures despite being on stable anti-epileptic drug regimens.[11]
• Endpoints: The primary endpoint is the mean percentage reduction in monthly seizure frequency during treatment with Basimglurant compared to placebo. Secondary endpoints include assessments of seizure duration and intensity, seizure-free days, and impact on quality of life.[11]
• Status: The trial has completed enrollment and the treatment phase, with the study completion date listed as April 2025 and primary completion in February 2025.[11]

Table 5: Overview of Noema Pharma Clinical Trials (TN & TSC)

	LibraTN Study (TN)	Galene Study (TSC)
Trial Identifier	NCT05217628	NCT05059327
Indication	Pain in Trigeminal Neuralgia	Seizures in Tuberous Sclerosis Complex
Phase	Phase II/III	Phase IIb
Study Design	Randomized Withdrawal	Randomized, Placebo-Controlled, Cross-Over
Target Population	Adults (18-75 yrs) with refractory TN	Children, adolescents, & young adults (5-30 yrs) with refractory seizures
Primary Endpoint	Reduction in pain frequency/severity	Mean % change in monthly seizure frequency
Status	Ongoing, Not Recruiting	Completed

Expert Analysis and Future Outlook

The developmental journey of Basimglurant is emblematic of key trends in modern drug development, particularly within the challenging landscape of central nervous system disorders. Its history, from a broad-market prospect at a major pharmaceutical company to a repurposed asset for rare diseases at a clinical-stage biotech, offers valuable lessons on strategy, risk, and the importance of translational science.

A Tale of Two Strategies: From "Blockbuster" to "Niche-Buster"

The trajectory of Basimglurant represents a profound strategic shift in pharmaceutical R&D philosophy. The initial approach by Roche embodied a traditional "blockbuster" model. It targeted large, heterogeneous patient populations in MDD and FXS, where the market potential was enormous but the underlying biology was complex and the mechanistic link to mGluR5 modulation was largely hypothetical. This high-risk, high-reward strategy relies on demonstrating a modest effect size in a large population, a notoriously difficult task in psychiatry, as evidenced by the high placebo response rates and ultimate failure of the MDD trial.

In contrast, Noema Pharma's strategy is a prime example of a modern, "niche-buster" or precision-medicine approach. By targeting rare diseases like TN and TSC, the focus shifts to smaller, more genetically or phenotypically homogeneous patient populations. Crucially, in these indications, the scientific rationale is much stronger; the link between the drug's mechanism (dampening glutamatergic hyperexcitability) and the core pathophysiology of the diseases (neuronal over-signaling) is direct and well-supported by preclinical models. This strategy accepts a smaller market size in exchange for a higher probability of scientific success and a clearer path to regulatory approval.

Probability of Success and Key Development Hurdles

The future of Basimglurant is balanced between significant strengths and considerable hurdles.

• Strengths: The compound's most significant asset is its well-characterized and favorable pharmacokinetic profile. Good oral bioavailability, a long half-life enabling once-daily dosing, and a low, well-defined potential for drug-drug interactions are invaluable properties that have already been established, significantly de-risking the development process. Furthermore, the strong, direct mechanistic rationale in both TN and TSC provides a much more solid scientific foundation than was present in the earlier programs. The FDA's granting of Fast Track designation for the TN indication further validates the potential of the drug to address a serious unmet need.
• Weaknesses and Hurdles: The primary hurdle for Basimglurant is the shadow of its past. The failure to demonstrate efficacy in two separate Phase II trials, even in different indications, creates a negative precedent that must be overcome with exceptionally robust and statistically persuasive new data. The most significant risk remains the safety profile, specifically the potential for rare but serious psychiatric adverse events like psychosis or mania. While the benefit-risk calculation may be favorable in the context of severe pain or refractory seizures, regulators will undoubtedly scrutinize this aspect with extreme care. The emergence of any new or concerning psychiatric signals in the ongoing trials could prove fatal to the programs.

Concluding Remarks and Future Trajectory

Basimglurant stands at a critical juncture. Its ultimate fate rests entirely on the outcomes of the LibraTN and Galene clinical trials. Positive, statistically significant data from either of these studies could pave the way for a New Drug Application (NDA) and the potential for regulatory approval, marking a remarkable resurrection for a compound once abandoned.

The story of Basimglurant serves as a powerful case study for the pharmaceutical industry. It illustrates the profound challenges of translating preclinical neuroscience into clinical success, the limitations of broad, hypothesis-driven approaches in complex psychiatric disorders, and the immense value of strategic repurposing. It underscores the principle that a drug's failure is often specific to an indication, not necessarily inherent to the molecule itself. A well-characterized compound with a sound pharmacological profile can find new life and create significant value when its mechanism of action is precisely matched with the right disease pathology. The next chapter for Basimglurant will reveal whether this targeted approach can finally unlock the therapeutic potential that has been pursued for over a decade.

Works cited

1. Basimglurant: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 27, 2025, https://go.drugbank.com/drugs/DB11833
2. RG7090 | CAS NO.:802906-73-6 | GlpBio, accessed September 27, 2025, https://www.glpbio.com/sp/rg7090.html
3. Basimglurant (RG7090) | mGlu5 NAM - MedchemExpress.com, accessed September 27, 2025, https://www.medchemexpress.com/RG7090.html
4. Basimglurant - Wikipedia, accessed September 27, 2025, https://en.wikipedia.org/wiki/Basimglurant
5. Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/28816242/
6. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/27304433/
7. Basimglurant: Development discontinued - BioCentury, accessed September 27, 2025, https://www.biocentury.com/article/216447/basimglurant-development-discontinued
8. Our Pipeline - Noema Pharma, accessed September 27, 2025, https://noemapharma.com/pipeline/
9. Noema Pharma receives FDA Fast Track designation, accessed September 27, 2025, https://noemapharma.com/2022/10/18/noema-pharma-receives-fda-fast-track-designation/
10. FDA Gives Fast Track Designation for Basimglurant in Individuals with Trigeminal Neuralgia, accessed September 27, 2025, https://practicalneurology.com/news/fda-gives-fast-track-designation-for-basimglurant-in-individuals-with-trigeminal-neuralgia/2470053/
11. Study Details | NCT05059327 | Basimglurant (NOE-101) in Children ..., accessed September 27, 2025, https://www.clinicaltrials.gov/study/NCT05059327
12. Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC | Clinical Research Trial Listing - CenterWatch, accessed September 27, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT05059327/basimglurant-in-children-adolescents-and-young-adults-with-tsc
13. BASIMGLURANT - gsrs, accessed September 27, 2025, https://ginas.ncats.nih.gov/ginas/app/substance/4ce56d04-ae78-49ca-a69f-777e49743fee
14. Basimglurant | mGlu5 negative allosteric modulator | Buy from Supplier AdooQ®, accessed September 27, 2025, https://www.adooq.com/basimglurant.html
15. Basimglurant | GluR - TargetMol, accessed September 27, 2025, https://www.targetmol.com/compound/basimglurant
16. Basimglurant Sulfate - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 27, 2025, https://synapse.patsnap.com/drug/e9c4af2a76da4658b55959b54e0c2c16
17. basimglurant | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 27, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9309
18. Basimglurant 98% | CAS: 802906-73-6 | AChemBlock, accessed September 27, 2025, https://www.achemblock.com/l13487-basimglurant.html
19. go.drugbank.com, accessed September 27, 2025, https://go.drugbank.com/drugs/DB11833#:~:text=This%20compound%20belongs%20to%20the,a%20CC%20or%20CN%20bond.
20. Basimglurant (RG-7090); CAS No:802906-73-6 - AOBIOUS, accessed September 27, 2025, https://aobious.com/aobious/metabotropic-glutamate-receptors/1850-basimglurant-rg-7090.html
21. Population Pharmacokinetic and Exposure–dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients - PubMed Central, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6132363/
22. Efficacy and Safety of Basimglurant as Adjunctive ... - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/304006954_Efficacy_and_Safety_of_Basimglurant_as_Adjunctive_Therapy_for_Major_Depression_A_Randomized_Clinical_Trial
23. (PDF) Translational Concepts of mGluR5 in Synaptic Diseases of ..., accessed September 27, 2025, https://www.researchgate.net/publication/233830929_Translational_Concepts_of_mGluR5_in_Synaptic_Diseases_of_the_Brain
24. Metabotropic glutamate receptors - Neurology, accessed September 27, 2025, https://www.neurology.org/doi/10.1212/01.wnl.0000306315.03021.2a
25. Translational Concepts of mGluR5 in Synaptic Diseases of the Brain - Frontiers, accessed September 27, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2012.00199/full
26. Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/272193400_Pharmacology_of_Basimglurant_RO4917523_RG7090_a_Unique_Metabotropic_Glutamate_Receptor_5_Negative_Allosteric_Modulator_in_Clinical_Development_for_Depression
27. Metabotropic Glutamate Receptor 5: A Potential Target for Neuropathic Pain Treatment, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11808587/
28. Loss of mGluR5 in D1 Receptor-Expressing Neurons Improves Stress Coping - MDPI, accessed September 27, 2025, https://www.mdpi.com/1422-0067/22/15/7826
29. Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5 - PubMed Central, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7705108/
30. Basimglurant for Trigeminal Neuralgia · Info for Participants - Clinical Trials, accessed September 27, 2025, https://www.withpower.com/trial/phase-2-and-3-neuralgia-2022-c1a01
31. Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5770759/
32. Novel Agent Falls Short of Expectations for Major Depression - Medscape, accessed September 27, 2025, https://www.medscape.com/viewarticle/866164
33. A double-tracer technique to characterize absorption, distribution ..., accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/27123695/
34. A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [(14)C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [(13)C6]-labeled basimglurant in humans - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/301697226_A_double-tracer_technique_to_characterize_absorption_distribution_metabolism_and_excretion_ADME_of_14C-basimglurant_and_absolute_bioavailability_after_oral_administration_and_concomitant_intravenous_m
35. (PDF) Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/309748807_Low_Potential_of_Basimglurant_to_Be_Involved_in_Drug-Drug_Interactions_Influence_of_Non-Michaelis-Menten_P450_Kinetics_on_Fraction_Metabolized
36. Basimglurant Completed Phase 1 Trials for Healthy Volunteers (HV) | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/drugs/DB11833/clinical_trials?conditions=DBCOND0114743&phase=1&status=completed
37. Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5 - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/26219727/
38. NCT02433093 | A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD) | ClinicalTrials.gov, accessed September 27, 2025, https://www.clinicaltrials.gov/study/NCT02433093
39. Basimglurant Completed Phase 1 Trials for Major Depressive Disorder, Healthy Volunteer, accessed September 27, 2025, https://go.drugbank.com/drugs/DB11833/clinical_trials?conditions=DBCOND0075604&phase=1&status=completed
40. Basimglurant Completed Phase 2 Trials for Major Depressive Disorder (MDD) Treatment, accessed September 27, 2025, https://go.drugbank.com/drugs/DB11833/clinical_trials?conditions=DBCOND0030181&phase=2&purpose=treatment&status=completed
41. Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results - eScholarship, accessed September 27, 2025, https://escholarship.org/uc/item/7mn4c9f6
42. Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents ..., accessed September 27, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770759/
43. CNS Trial Failures: Using the Fragile X Syndrome-mGluR5 drug target to highlight the complexities of translating preclinical discoveries into human trials - PMC - PubMed Central, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9060375/
44. From Discovery to Innovative Translational Approaches in 80 Years of Fragile X Syndrome Research - MDPI, accessed September 27, 2025, https://www.mdpi.com/2227-9059/13/4/805
45. An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. | Clinical Research Trial Listing - CenterWatch, accessed September 27, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT05217628/an-efficacy-and-safety-study-of-basimglurant-in-patients-with-trigeminal-neuralgia
46. Study Details | NCT05217628 | An Efficacy and Safety Study of ..., accessed September 27, 2025, https://www.clinicaltrials.gov/study/NCT05217628
47. The Molecular Basis and Pathophysiology of Trigeminal Neuralgia - MDPI, accessed September 27, 2025, https://www.mdpi.com/1422-0067/23/7/3604
48. TRIGEMINAL NEURALGIA: NEUROPATHIC PAIN ORIGINATING IN THE CNS - Biolife, accessed September 27, 2025, https://www.biolife-publisher.it/ejnd/2024/04/17/trigeminal-neuralgia-neuropathic-pain-originating-in-the-cns/
49. Pathogenesis, Diagnosis, and Management of Trigeminal Neuralgia: A Narrative Review, accessed September 27, 2025, https://www.mdpi.com/2077-0383/14/2/528
50. Metabotropic glutamate receptor 5 contributes to inflammatory tongue pain via extracellular signal-regulated kinase signaling in the trigeminal spinal subnucleus caudalis and upper cervical spinal cord - PMC - PubMed Central, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3543209/
51. A Phase II/III efficacy and safety study of basimglurant in patients with trigeminal neuralgia, accessed September 27, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-phase-iiiii-efficacy-and-safety-study-of-basimglurant-in-patients-with-trigeminal-neuralgia/
52. Libra Study© for Trigeminal Neuralgia - Facial Pain Association, accessed September 27, 2025, https://www.facepain.org/libra-study-for-trigeminal-neuralgia/
53. Noema Pharma announces completion of enrollment in the Trigeminal Neuralgia Electronic Diary (T N ED) validation studY, accessed September 27, 2025, https://noemapharma.com/2022/09/06/noemapharmaannouncescompletionofenrollmentinthetrigeminalneuralgiaelectronicdiarytnedvalidationstudy/
54. Cellular localization of metabotropic glutamate receptors in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex - Erasmus University Rotterdam, accessed September 27, 2025, https://pure.eur.nl/en/publications/cellular-localization-of-metabotropic-glutamate-receptors-in-cort
55. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment - MDPI, accessed September 27, 2025, https://www.mdpi.com/1422-0067/22/13/6677
56. The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC) - Frontiers, accessed September 27, 2025, https://www.frontiersin.org/journals/neuroanatomy/articles/10.3389/fnana.2020.00039/full
57. Episode 33: Noema, Basimglurant and a New Clinical Trial for Seizures in TSC, accessed September 27, 2025, https://www.tscalliance.org/resources/episode-33-noema-basimglurant-and-a-new-clinical-trial-for-seizures-in-tsc/
58. mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/29206810/
59. (PDF) MGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/321578853_MGluR5_Modulation_of_Behavioral_and_Epileptic_Phenotypes_in_a_Mouse_Model_of_Tuberous_Sclerosis_Complex
60. Basimglurant, a new mechanism of action for control of seizures in tuberous sclerosis complex? - TSC Alliance, accessed September 27, 2025, https://www.tscalliance.org/tsc-matters/basimglurant-a-new-mechanism-of-action-for-control-of-seizures-in-tuberous-sclerosis-complex/
61. Participants needed for important TSC-related epilepsy clinical trial, accessed September 27, 2025, https://tuberous-sclerosis.org/galene-clinical-trial/
62. Basimglurant in children, adolescents, and young adults with Tuberous Sclerosis Complex, accessed September 27, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/basimglurant-in-children-adolescents-and-young-adults-with-tuberous-sclerosis-complex/